Movalis (Meloxicam)

Meloxicam selectively inhibits the cyclooxygenase‑2 (COX‑2) enzyme, which lowers the production of prostaglandins—chemical mediators that cause inflammation, pain, and fever. By targeting COX‑2 more than COX‑1, it aims to provide anti‑inflammatory and analgesic effects while preserving some gastric protection.

The appropriate dose of Movalis is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Dosage recommendations are provided in the product labeling and should be followed as directed by a healthcare professional.

The safety of meloxicam in pregnancy and lactation has not been definitively established. It is generally advised to avoid use during the third trimester and to discuss potential risks with a healthcare provider. Breastfeeding mothers should also consult a physician before using the medication.

To place an order, submit an enquiry on the Movalis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam offers a higher degree of COX‑2 selectivity, which may reduce the incidence of gastrointestinal irritation while still providing effective anti‑inflammatory and analgesic action. However, cardiovascular and renal risks remain similar to other NSAIDs and must be evaluated individually.

Movalis should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, direct sunlight, and extreme heat to maintain product stability throughout its shelf life.

Movalis is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food may lessen gastrointestinal discomfort. The exact administration schedule should follow the prescriber’s instructions.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), liver injury, renal impairment, and anaphylactic reactions. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Movalis is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, patients with severe heart failure, and anyone who has experienced a serious allergic reaction to a COX‑2 inhibitor. It should also be used with caution in the elderly and in patients with renal or hepatic impairment.